{"brief_title": "Oral Enzastaurin HCl in Patients With Relapsed Mantle Cell Lymphoma", "brief_summary": "The purposes of this study are to determine the safety of oral enzastaurin HCl and any side effects that might be associated with it and whether enzastaurin HCl can help patients with Mantle Cell Lymphoma.", "condition": "Mantle-Cell Lymphoma", "intervention_type": "Drug", "intervention_name": "enzastaurin", "description": "500 mg, oral, daily, up to six 28 day cycles", "arm_group_label": "A", "other_name": "LY317615", "criteria": "Inclusion Criteria: - Mantle Cell Lymphoma - Previous treatment for Mantle Cell Lymphoma - Adequate organ function Exclusion Criteria: - Inability to swallow tablets - Must not have had more than 3 prior treatments for Mantle Cell Lymphoma - Must not have significant heart problems", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00088205.xml"}